- about us
- medical affairs
- investors & media
- Email Alerts
- Contact Us
TX-004HR is a vaginal 17β-estradiol investigational product under development for treatment of dyspareunia (vaginal pain from sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. The VagiCap™ softgel capsule technology being utilized was designed for simple delivery.
The Phase 3 Rejoice Trial has been completed. Positive topline data presented Q4 2015.
TX-001HR is an investigational oral 17ß-estradiol and progesterone combination product under development using SYMBODA™ technology for treatment of vasomotor symptoms (VMS), including hot flashes and night sweats, related to menopause. It is an oral softgel capsule designed for simple delivery.
The Phase 3 Replenish Trial was fully enrolled Q3 2015. Topline data anticipated Q4 2016 - Q1 2017.
For more information about TherapeuticsMD clinical trials please visit ClinicalTrials.gov.